Immunological treatment of multiple sclerosis

被引：14

作者：

Diebold, Martin

Derfuss, Tobias ^{[1
,2
]}

机构：

[1] Univ Basel Hosp, Dept Neurol, Petersgraben 4, CH-4031 Basel, Switzerland

[2] Univ Basel Hosp, Dept Biomed, Petersgraben 4, CH-4031 Basel, Switzerland

来源：

SEMINARS IN HEMATOLOGY | 2016年 / 53卷 / 02期

关键词：

Multiple sclerosis; Clinically isolated syndrome; Immunomodulation; PLACEBO-CONTROLLED PHASE-3; VARICELLA-ZOSTER-VIRUS; DOUBLE-BLIND; INTERFERON BETA-1A; INTRAMUSCULAR INTERFERON; ORAL TERIFLUNOMIDE; DEMYELINATING EVENT; DISEASE-ACTIVITY; CONTROLLED TRIAL; FINGOLIMOD;

D O I：

10.1053/j.seminhematol.2016.04.016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment of multiple sclerosis (MS) has been a challenge since its first description by Charcot. The advent of immunomodulatory drugs in the mid 1990s brought the first big change in the treatment of MS patients. During the last 10 years there has been an ongoing tremendous evolution of novel treatment options for relapsing-remitting MS. These options include monoclonal antibodies, which inhibit migration of lymphocytes (natalizumab), deplete lymphocytes (alemtuzumab), or block the cytokine receptor interleukin (IL)-2 (daclizumab), teriflunomide that inhibits proliferation of activated lymphocytes, fingolimod that modulates the sphingosine-receptor system, and dimethylfumarate that combines features of immunomodulatory and immunosuppressive drugs. The topic of this review is to discuss currently available treatments and provide an outlook into the near future. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：S54 / S57

页数：4

共 47 条

[1] Varicella-Zoster Virus Infections in Patients Treated With Fingolimod Risk Assessment and Consensus Recommendations for Management [J].

Arvin, Ann M. ;

Wolinsky, Jerry S. ;

Kappos, Ludwig ;

Morris, Michele I. ;

Reder, Anthony T. ;

Tornatore, Carlo ;

Gershon, Anne ;

Gershon, Michael ;

Levin, Myron J. ;

Bezuidenhoudt, Mauritz ;

Putzki, Norman .

JAMA NEUROLOGY, 2015, 72 (01) :31-39

[2] Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study [J].

Calabresi, Peter A. ;

Kieseier, Bernd C. ;

Arnold, Douglas L. ;

Balcer, Laura J. ;

Boyko, Alexey ;

Pelletier, Jean ;

Liu, Shifang ;

Zhu, Ying ;

Seddighzadeh, All ;

Hung, Serena ;

Deykin, Aaron .

LANCET NEUROLOGY, 2014, 13 (07) :657-665

[3] Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial [J].

Calabresi, Peter A. ;

Radue, Ernst-Wilhelm ;

Goodin, Douglas ;

Jeffery, Douglas ;

Rammohan, Kottil W. ;

Reder, Anthony T. ;

Vollmer, Timothy ;

Agius, Mark A. ;

Kappos, Ludwig ;

Stites, Tracy ;

Li, Bingbing ;

Cappiello, Linda ;

von Rosenstiel, Philipp ;

Lublin, Fred D. .

LANCET NEUROLOGY, 2014, 13 (06) :545-556

[4] FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation [J].

Choi, Ji Woong ;

Gardell, Shannon E. ;

Herr, Deron R. ;

Rivera, Richard ;

Lee, Chang-Wook ;

Noguchi, Kyoko ;

Teo, Siew Teng ;

Yung, Yun C. ;

Lu, Melissa ;

Kennedy, Grace ;

Chun, Jerold .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (02) :751-756

[5] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[6] Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis [J].

Cohen, Jeffrey A. ;

Barkhof, Frederik ;

Comi, Giancarlo ;

Hartung, Hans-Peter ;

Khatri, Bhupendra O. ;

Montalban, Xavier ;

Pelletier, Jean ;

Capra, Ruggero ;

Gallo, Paolo ;

Izquierdo, Guillermo ;

Tiel-Wilck, Klaus ;

de Vera, Ana ;

Jin, James ;

Stites, Tracy ;

Wu, Stacy ;

Aradhye, Shreeram ;

Kappos, Ludwig .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) :402-415

[7] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial [J].

Coles, Alasdair J. ;

Twyman, Cary L. ;

Arnold, Douglas L. ;

Cohen, Jeffrey A. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Miller, Tamara ;

Fisher, Elizabeth ;

Sandbrink, Rupert ;

Lake, Stephen L. ;

Margolin, David H. ;

Oyuela, Pedro ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1829-1839

[8] Body fluid biomarkers in multiple sclerosis [J].

Comabella, Manuel ;

Montalban, Xavier .

LANCET NEUROLOGY, 2014, 13 (01) :113-126

[9] Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial [J].

Comi, G. ;

Martinelli, V. ;

Rodegher, M. ;

Moiola, L. ;

Bajenaru, O. ;

Carra, A. ;

Elovaara, I. ;

Fazekas, F. ;

Hartung, H. P. ;

Hillert, J. ;

King, J. ;

Komoly, S. ;

Lubetzki, C. ;

Montalban, X. ;

Myhr, K. M. ;

Ravnborg, M. ;

Rieckmann, P. ;

Wynn, D. ;

Young, C. ;

Filippi, M. .

LANCET, 2009, 374 (9700) :1503-1511

[10] Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial [J].

Comi, Giancarlo ;

De Stefano, Nicola ;

Freedman, Mark S. ;

Barkhof, Frederik ;

Polman, Chris H. ;

Uitdehaag, Bernard M. J. ;

Casset-Semanaz, Florence ;

Hennessy, Brian ;

Moraga, Margaretha Stam ;

Rocak, Sanda ;

Stubinski, Bettina ;

Kappos, Ludwig .

LANCET NEUROLOGY, 2012, 11 (01) :33-41

← 1 2 3 4 5 →